News & Events
Location: United Kingdom, England
Employees: 11-50
Total raised: $12.41M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Internatio... | ibtplc.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.07.2015 | Series A | $12.41M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.06.2023 | Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7) | Stevenage, UK - 13 June 2023 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that a Phase Ib trial... |
| 18.12.2017 | Boehringer antes up on a €627.5M deal for rights to Autifony’s schizophrenia drugs | Boehringer Ingelheim has lined up an option on the schizophrenia drugs under development at GSK spinout Autifony, including the lead therapy AUT00206. Jan Poth Starting with a €25 million upfront fee, with another €17.... |
| 15.03.2017 | Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia | London, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £8... |
| 10.07.2015 | Autifony Therapeutics Raises £8M in Series A Funding | Autifony Therapeutics Limited, a London, UK developer of novel pharmaceutical treatments for hearing disorders, closed an £8m extension to its Series A funding round. Backers included SV Life Sciences, Imperial Innovations, Pfizer Venture I... |
| 16.06.2014 | Autifony Therapeutics Receives £2.2M Grant from Technology Strategy Board | Autifony Therapeutics Limited, a London, UK-based developer of novel pharmaceutical treatments for hearing disorders, rewceived a £2.2m grant from the Technology Strategy Board (TSB). Autifony, an Imperial Innovations Group plc (AIM: IVO)’s... |
| 06.12.2011 | TopiVert Raises £8M | TopiVert, a London, UK-based start-up that focuses on developing topical medicines for inflammatory diseases of the eye and gut, has raised £8m in funding. Backers include Imperial Innovations Group (AIM: IVO) and SV Life Sciences. TopiVert... |